We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CFDA Provides Guidelines for Devicemakers Awaiting GMP Inspections

CFDA Provides Guidelines for Devicemakers Awaiting GMP Inspections

November 27, 2015

The China Food and Drug Administration has issued four guidelines that provide additional information for devicemakers awaiting good manufacturing practices inspections.

Covering GMP inspections in general, sterile devices, implantable devices and in vitro diagnostics, the guidelines are annexes to the main device GMP regulations issued in January, Ropes & Gray Partner Katherine Wang says. Mainly, they offer guidance to inspectors on how they should inspect manufacturing facilities, but they also can help companies prepare because they list what inspectors will look for when they conduct onsite GMP inspections.

“The appendixes set forth principles for the specific types of devices that represent higher risk,” Wang says.

Ames Gross, president of Pacific Bridge Medical, says the new guidelines should help with the overall quality of medical device manufacturing in China. “There is not much change for foreign companies manufacturing in China, since they already implement their own GMP,” he says. “However, the quality standards should improve for domestic Chinese companies that comply with the new guidelines, which would make Chinese-made devices more competitive globally.”

It has been a busy year for the CFDA in terms of ramping up device quality. In January, the regulator announced it would beef up its inspections system for medical devices by adding more investigators and improving the performance of quality testing centers. The changes also called for stronger leadership at the CFDA and local FDAs, better staff training, greater information sharing and a more coordinated approach.

The following month, China released revised GMPs for sterile and implantable devices.

Over the summer, China’s State Council unveiled new guidelines intended to make the medical device approval process more science-based and efficient. The guidelines, which affect pharmaceuticals, look to raise the review standards to those of international levels while helping enhance transparency throughout the device approval process. To that end, the council is aiming to improve registration, technical review, product testing and field inspection conditions.

Stay up to date on Chinese regulations with our management report Understanding China’s New Medical Device Regulations, and you will be fully prepared when the country’s Food and Drug Administration shows up for a surprise inspection!

Medical Devices Regulatory Affairs

Upcoming Events

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

  • 08Mar

    Medical Device Cybersecurity: The Regulatory Landscape and How to Defend Your Practices During an Inspection

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Boston Scientific’s Single Use Ureteroscope Gets FDA Clearance

  • Gilead’s Trodelvy Gets Expanded Approval in Breast Cancer

  • AI Software to Improve Echocardiogram Images Gets FDA Clearance

  • Rocket Pharmaceuticals Gets RMAT Designation for Danon Disease Gene Therapy

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing